Starting Recovery From Opioid Addiction Without Getting Clean First — How the Naltrexone Transition Works
For many people with opioid dependence, the hardest part of considering naltrexone is the transition into it. They want treatment but fear the withdrawal that can occur between stopping opioids and receiving an antagonist. DeBinge’s programme is designed around this problem.
Naltrexone blocks opioid receptors. If introduced while a person is still dependent on opioids, it can cause precipitated withdrawal. Conventional induction generally requires opioid abstinence beforehand and clinical confirmation of readiness. This is a safety issue, not a test of character.
Why an opioid-free interval is often discussed
Naltrexone blocks opioid receptors. If introduced while a person is still dependent on opioids, it can cause precipitated withdrawal. Conventional induction generally requires opioid abstinence beforehand and clinical confirmation of readiness. This is a safety issue, not a test of character.
What ‘without getting clean first’ means at DeBinge
The clinic describes a supervised pathway that allows selected patients to present for treatment without first completing a separate opioid-free waiting window on their own. It uses a buprenorphine-based transition before implantation. This does not mean naltrexone can be inserted safely at any moment after opioid use.
The supervised bridge
According to DeBinge’s described protocol, buprenorphine is introduced and then tapered over several days under medical observation. Implant timing is individualized; the clinic describes overlap as buprenorphine clears and naltrexone release begins. Only the treating clinical team can decide when this is safe, particularly after fentanyl or methadone.
What happens after the implant?
DeBinge describes the O’Neil Long-Acting Naltrexone Implant as offering its strongest craving and relapse-prevention support for roughly nine months on average, with receptor blockade potentially lasting longer in some patients. The duration is variable and does not guarantee protection from overdose.
Long-term recovery needs more than blockade
The clinic describes a year of counselling after treatment. Patients should discuss relapse planning, local follow-up and what to do if they need surgery, pain management or emergency care. The implant is not FDA-approved in the United States.
Questions before booking
Ask about medical eligibility, withdrawal monitoring, implant complications, costs, accommodation, emergency transfers and follow-up. Be completely honest about fentanyl, methadone, buprenorphine, alcohol and sedative use. Never try to recreate a specialist induction process without medical supervision.
Talk through your treatment options
Recovery is individual. A qualified addiction clinician can help you weigh treatment options, risks and next steps. For details of DeBinge’s Bahamas programme, request a confidential consultation.
Medical information: This page is educational and does not replace individualized medical advice. DeBinge’s long-acting naltrexone implant is not FDA-approved in the United States. Do not discontinue prescribed medication without clinical supervision. In a medical emergency, contact local emergency services.